Cardiol Therapeutics Inc. (CRDL.TO) Research

Cardiol Therapeutics Inc. operates as a clinical-stage life sciences company, primarily engaged in the discovery and advancement of treatments designed to combat fibrosis and inflammation within the context of cardiovascular diseases. Its flagship product, CardiolRx, is currently undergoing a significant Phase II/III international clinical trial. This extensive study is randomized, double-blind, and placebo-controlled, evaluating CardiolRx's efficacy and safety as a heart-protective therapy to mitigate cardiovascular and respiratory issues in individuals hospitalized with COVID-19. Concurrently, the trial also assesses CardiolRx's role in addressing acute myocarditis. Beyond this, the company is developing an injectable, subcutaneous formulation of CardiolRx, intended to target cardiac scarring and inflammation that contribute to the development and worsening of heart failure. Established in 2017, Cardiol Therapeutics Inc. is based in Oakville, Canada.

Market snapshot

Symbol
CRDL.TO
Price
$1.51
Day change
+0.33%
Market cap
$173.5M
P/E ratio
-3.85x
52-week range
1.225-2.33
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Next earnings
in 2 months

Peer companies

  • BioNxt Solutions Inc. (BNXT.CN)
  • Grown Rogue International Inc. (GRIN.CN)
  • HLS Therapeutics Inc. (HLS.TO)
  • Jushi Holdings Inc. (JUSH.CN)
  • Cannara Biotech Inc. (LOVE.V)
  • Satellos Bioscience Inc. (MSCL.TO)
  • Planet 13 Holdings Inc. (PLTH.CN)
  • BioSyent Inc. (RX.V)

Open Cardiol Therapeutics Inc. (CRDL.TO) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.